CINECA IRIS Institutional Research Information System

GIORDANO, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.315
EU - Europa 5.103
AS - Asia 4.784
SA - Sud America 95
AF - Africa 74
OC - Oceania 64
Continente sconosciuto - Info sul continente non disponibili 12
Totale 19.447
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.137
CN - Cina 2.762
IT - Italia 1.158
SG - Singapore 718
DE - Germania 588
IE - Irlanda 586
SE - Svezia 511
FR - Francia 458
GB - Regno Unito 373
UA - Ucraina 371
FI - Finlandia 331
KR - Corea 320
JP - Giappone 238
PL - Polonia 181
IN - India 143
CA - Canada 125
VN - Vietnam 115
AT - Austria 102
HK - Hong Kong 86
TW - Taiwan 85
NL - Olanda 84
TR - Turchia 77
ID - Indonesia 74
ES - Italia 73
BR - Brasile 54
BE - Belgio 53
AU - Australia 52
IR - Iran 46
MX - Messico 44
RU - Federazione Russa 37
EG - Egitto 33
GR - Grecia 31
CZ - Repubblica Ceca 29
MY - Malesia 29
CH - Svizzera 27
TH - Thailandia 22
CL - Cile 17
RO - Romania 17
PT - Portogallo 16
DK - Danimarca 14
HU - Ungheria 14
NZ - Nuova Zelanda 12
SN - Senegal 12
AR - Argentina 11
IL - Israele 11
EU - Europa 10
NO - Norvegia 10
AM - Armenia 9
HR - Croazia 7
RS - Serbia 7
SK - Slovacchia (Repubblica Slovacca) 7
UZ - Uzbekistan 7
ZA - Sudafrica 7
GT - Guatemala 6
PE - Perù 6
SI - Slovenia 6
KE - Kenya 5
NG - Nigeria 5
PK - Pakistan 5
PS - Palestinian Territory 5
CO - Colombia 4
LK - Sri Lanka 4
SA - Arabia Saudita 4
DZ - Algeria 3
GH - Ghana 3
MO - Macao, regione amministrativa speciale della Cina 3
QA - Qatar 3
AZ - Azerbaigian 2
BG - Bulgaria 2
ET - Etiopia 2
IM - Isola di Man 2
IQ - Iraq 2
JO - Giordania 2
LT - Lituania 2
LV - Lettonia 2
OM - Oman 2
PH - Filippine 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
GE - Georgia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
PY - Paraguay 1
SV - El Salvador 1
YE - Yemen 1
Totale 19.447
Salva come PNG Salva come JPEG
Città #
Chandler 933
Beijing 813
Ann Arbor 810
Dublin 584
Santa Clara 569
Fairfield 534
Singapore 533
Houston 453
Woodbridge 300
Ashburn 294
Wilmington 266
Dearborn 250
Jacksonville 240
Villeurbanne 234
Princeton 209
Seattle 201
Shanghai 200
Cambridge 194
Medford 187
Guangzhou 183
Nyköping 175
Torino 165
Columbus 159
Warsaw 142
Redwood City 137
Nanjing 133
Pisa 115
Turin 106
Milan 103
Boston 100
Hangzhou 99
Vienna 83
Jakarta 67
Jinan 67
Wuhan 64
Zhengzhou 62
Dong Ket 61
Tokyo 58
Boardman 53
Cagliari 52
Taipei 51
Chengdu 50
New York 49
Shenyang 47
Hefei 44
Helsinki 43
Los Angeles 42
Munich 42
San Diego 41
Brussels 40
Fremont 40
Tianjin 37
Changsha 36
Toronto 35
Verona 33
London 32
Ottawa 30
Rome 30
Falls Church 29
Pittsburgh 29
Kunming 26
Changchun 25
Hong Kong 25
Norwalk 25
Seoul 25
Xian 25
Groningen 24
Nuremberg 24
Hebei 23
Buffalo 22
Chongqing 22
Eschweiler 22
Florence 22
Madrid 20
Nanchang 20
Mountain View 18
Philadelphia 18
Washington 18
Phoenix 17
Silver Spring 17
Barcelona 16
Genoa 16
Lachine 16
Mumbai 16
Harbin 15
Istanbul 14
Fuzhou 13
São Paulo 13
Amsterdam 12
Central District 12
Dallas 12
Düsseldorf 12
Lanzhou 12
Paris 12
Shenzhen 12
Bangkok 11
Bethesda 11
Brescia 11
Carrara 11
Pune 11
Totale 11.464
Salva come PNG Salva come JPEG
Nome #
The Dual Roles of NRF2 in Cancer 2.275
YAP activation is an early event and a potential therapeutic target in liver cancer development. 740
MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC. 447
How Can Gastric Cancer Molecular Profiling Guide Future Therapies? 399
MicroRNAs: New tools for diagnosis, prognosis and therapy in hepatocellular carcinoma? 340
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. 336
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. 307
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts 296
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 284
Personalized therapeutic strategies in HER2-driven gastric cancer 270
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 262
Enhanced c-Met activity promotes G-CSF induced mobilization of hematopoietic progenitor cells via ROS signaling. 260
Only a subset of Met-activated pathways are required to sustain oncogene addiction 253
By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. 250
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 231
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits 229
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC 220
Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3 210
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. 205
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 198
Resistance to targeted therapies: a role for microRNAs? 196
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies 195
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 189
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. 187
Met as a therapeutic target in HCC: Facts and hopes. 186
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 184
Istologia Medica 172
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis 160
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis 156
miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling 150
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. 149
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer. 149
Downregulating Neuropilin-2 Triggers a Novel Mechanism Enabling EGFR-Dependent Resistance to Oncogene-Targeted Therapies 148
Activation of RAS family members confers resistance to ROS1 targeting drugs. 147
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 145
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis 144
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth 142
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. 139
Biosynthesis of the protein encoded by the c-met proto-oncogene 129
From single- to multi- target drugs in cancer therapy: when aspecificity becomes an advantage 125
Targeted therapies in cancer and mechanisms of resistance. 123
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort 123
MicroRNAs impair MET-mediated invasive growth 119
A point mutation in the MET oncogene abrogates metastasis without affecting transformation. 118
Targeted therapies for gastric cancer: failures and hopes from clinical trials 117
Different point mutations in the met oncogene elicit distinct biological properties. 115
Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. 112
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 111
MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer 110
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 104
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 98
Molecular cancer therapy: can our expectation be met? 97
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. 96
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas 95
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. 94
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 94
C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells. 93
Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. 91
A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation 91
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 91
Ets up-regulates MET transcription 90
The Semaphorin 4D receptor controls invasive growth by coupling with Met 89
Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility 89
Tyrosine kinase receptor indistinguishable from the c-met protein. 88
A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer 87
CD100/Plexin-B1 interactions sustain proliferation and survival of normal and Leukemic CD5+ B lymphocytes 86
Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility 86
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity 84
Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). 83
Autocrine signaling of NRP1 ligand galectin-1 elicits resistance to BRAF-targeted therapy in melanoma cells 83
A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine 83
Altered regulation of receptor associated-tyrosine kinases in human tumors 82
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 81
Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line. 81
C-terminal truncated forms of Met, the hepatocyte growth factor receptor. 81
Proteins phosphorylated on tyrosine as markers of human tumor cell lines 79
Control of invasive growth by the HGF receptor family. 79
Human ASH-1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells. 78
Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor). 78
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 78
The landscape of d16HER2 splice variant expression across HER2-positive cancers 77
Semaphorin 4D regulates gonadotropin hormone-releasing Hormone-1 neuronal migration through Plexin B1-Met Complex 76
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. 76
The c-met/HGF receptor in human tumours. 75
Hepatocyte growth factor is a regulator of monocyte-macrophage function 75
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. 75
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC. 75
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers 75
Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis 73
Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC 73
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages 72
Silencing the MET oncogene leads to regression of experimental tumors and metastases 71
HGF/MET signaling protects Plasmodium infected host cells from apoptosis 70
Drug development of met inhibitors: targeting oncogene addiction and expedience 68
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 67
MET overexpression turns human primary osteoblasts into osteosarcomas 66
Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. 65
MET receptor is overexpressed but not mutated in oral squamous cell carcinomas 65
Microsatellite instability in Gastric Cancer: Between lights and shadows 65
Diverse MicroRNAs-mRNA networks regulate the priming phase of mouse liver regeneration and of direct hyperplasia 65
Totale 16.385
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.634
article - articoli 0
book - libri 0
conference - conferenze 715
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.349
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.326 0 0 0 0 0 0 338 197 273 216 201 101
2020/20212.130 152 130 168 236 150 144 215 105 208 204 145 273
2021/20222.896 198 227 225 290 133 119 166 158 121 199 586 474
2022/20233.123 325 234 94 263 315 686 223 204 376 64 194 145
2023/20241.832 242 288 102 121 97 224 88 107 52 126 167 218
2024/20252.239 91 262 152 448 865 356 65 0 0 0 0 0
Totale 19.981